PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
David H. Ilson, MD, PhD - Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer
Go online to PeerView.com/GZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert oncologist reviews the latest evidence and recent developments in gastric cancer care, including innovative targeted therapeutics, and offers strategies to optimally navigate patient care and integrate novel therapeutics into treatment plans. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.